The in-vitro and in-vivo efficacy of cisplatin and analogues in the treatment of herpes simplex virus-II infections

The antitumour effect of cisplatin results from cross-linking and disruption of DNA when it binds to DNA bases, especially cytosine and guanine. Since herpes simplex virus (HSV) has a high cytosine and guanine content, cisplatin might be expected to have an antiviral effect against HSV. The 50% inhi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 1987-06, Vol.19 (6), p.815-822
Main Authors: Snyder, Michael B., Saravolatz, Louis D., Markowitz, Norman, Pohlod, Donald, Taylor, R. Craig, Ward, Sarah G.
Format: Article
Language:English
Subjects:
Animals
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Biological and medical sciences
Cisplatin - pharmacology
Cisplatin - toxicity
Female
Herpes Simplex - drug therapy
herpes simplex virus 2
Medical sciences
Mice
Pharmacology. Drug treatments
Structure-Activity Relationship
Virus Replication - drug effects
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c299t-f27b38a393effbc0eb3eca8681ebdcbfc0990c20adccdea1a7bd32244ad68a693
cites
container_end_page 822
container_issue 6
container_start_page 815
container_title Journal of antimicrobial chemotherapy
container_volume 19
creator Snyder, Michael B.
Saravolatz, Louis D.
Markowitz, Norman
Pohlod, Donald
Taylor, R. Craig
Ward, Sarah G.
description The antitumour effect of cisplatin results from cross-linking and disruption of DNA when it binds to DNA bases, especially cytosine and guanine. Since herpes simplex virus (HSV) has a high cytosine and guanine content, cisplatin might be expected to have an antiviral effect against HSV. The 50% inhibitory concentration of cisplatin for HSV-II was 0.06 mg/1. Six of ten platinum analogues had 50% inhibition of plaques at ≤ 10 mg/1. We evaluated the in-vivo activity of cisplatin against the MS strain of HSV-II in the mouse genital HSV model. Mice were treated either intraperitoneally or intravaginally beginning at 3 or 51 h after inoculation. In the intraperitoneally treated groups infection rates were lower, but not significantly; 4 of 15 in the 3-h and 7 of 15 in the 51-h group, compared to 9 of 15 in the untreated control group (P>0.18, chi-square test). Intravaginal cisplatin demonstrated a significant reduction of the infection rate from 10 of 15 untreated controls, compared to 5 of 18 in the 3-h and 5 of 17 in the 51-h group (P < 0.05, chi-square test). No toxic effects of intravaginal cisplatin were seen in uninfected mice. These studies suggest that platinum containing drugs warrant further evaluation as a new class of antiviral agents with activity against HSV.
doi_str_mv 10.1093/jac/19.6.815
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_14876158</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>14876158</sourcerecordid><originalsourceid>FETCH-LOGICAL-c299t-f27b38a393effbc0eb3eca8681ebdcbfc0990c20adccdea1a7bd32244ad68a693</originalsourceid><addsrcrecordid>eNo90M9rFDEUB_AgSl2rN6_CHMRTZ5sfM5nkKEW7C1sUaWnpJbzJvNjU-WWSXdr_3tRd9hTC9_Mejy8hHxldMqrF-SPYc6aXcqlY_YosWCVpyalmr8mCClqXTVWLt-RdjI-UUllLdUJOhMyjVC1IvH7Awo_lzqcwFTB2-89uKtA5b8E-F5MrrI9zD8mP_wWM0E-_txizLVKeTwEhDTimF_uAYc5R9MPc41Ox82Eby_U6W4c2-WmM78kbB33ED4f3lNx8_3Z9sSo3Py7XF183peVap9LxphUKhBb5lNZSbAVaUFIxbDvbOku1ppZT6KztEBg0bSc4ryropAKpxSn5st87h-lvPjeZwUeLfQ8jTttoWKUayWqV4dke2jDFGNCZOfgBwrNh1Lx0bHLHhmkjTe4480-Hvdt2wO6ID6Xm_PMhh2ihdwHGXOCRKc6bmvLMyj3zMeHTMYbwx8hGNLVZ3d2bza-r1e3Pq8rU4h_-ZZZj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>14876158</pqid></control><display><type>article</type><title>The in-vitro and in-vivo efficacy of cisplatin and analogues in the treatment of herpes simplex virus-II infections</title><source>Oxford University Press:Jisc Collections:Oxford Journal Archive: Access period 2024-2025</source><creator>Snyder, Michael B. ; Saravolatz, Louis D. ; Markowitz, Norman ; Pohlod, Donald ; Taylor, R. Craig ; Ward, Sarah G.</creator><creatorcontrib>Snyder, Michael B. ; Saravolatz, Louis D. ; Markowitz, Norman ; Pohlod, Donald ; Taylor, R. Craig ; Ward, Sarah G.</creatorcontrib><description>The antitumour effect of cisplatin results from cross-linking and disruption of DNA when it binds to DNA bases, especially cytosine and guanine. Since herpes simplex virus (HSV) has a high cytosine and guanine content, cisplatin might be expected to have an antiviral effect against HSV. The 50% inhibitory concentration of cisplatin for HSV-II was 0.06 mg/1. Six of ten platinum analogues had 50% inhibition of plaques at ≤ 10 mg/1. We evaluated the in-vivo activity of cisplatin against the MS strain of HSV-II in the mouse genital HSV model. Mice were treated either intraperitoneally or intravaginally beginning at 3 or 51 h after inoculation. In the intraperitoneally treated groups infection rates were lower, but not significantly; 4 of 15 in the 3-h and 7 of 15 in the 51-h group, compared to 9 of 15 in the untreated control group (P&gt;0.18, chi-square test). Intravaginal cisplatin demonstrated a significant reduction of the infection rate from 10 of 15 untreated controls, compared to 5 of 18 in the 3-h and 5 of 17 in the 51-h group (P &lt; 0.05, chi-square test). No toxic effects of intravaginal cisplatin were seen in uninfected mice. These studies suggest that platinum containing drugs warrant further evaluation as a new class of antiviral agents with activity against HSV.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/19.6.815</identifier><identifier>PMID: 3610908</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Animals ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; Cisplatin - pharmacology ; Cisplatin - toxicity ; Female ; Herpes Simplex - drug therapy ; herpes simplex virus 2 ; Medical sciences ; Mice ; Pharmacology. Drug treatments ; Structure-Activity Relationship ; Virus Replication - drug effects</subject><ispartof>Journal of antimicrobial chemotherapy, 1987-06, Vol.19 (6), p.815-822</ispartof><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c299t-f27b38a393effbc0eb3eca8681ebdcbfc0990c20adccdea1a7bd32244ad68a693</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=8227502$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3610908$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Snyder, Michael B.</creatorcontrib><creatorcontrib>Saravolatz, Louis D.</creatorcontrib><creatorcontrib>Markowitz, Norman</creatorcontrib><creatorcontrib>Pohlod, Donald</creatorcontrib><creatorcontrib>Taylor, R. Craig</creatorcontrib><creatorcontrib>Ward, Sarah G.</creatorcontrib><title>The in-vitro and in-vivo efficacy of cisplatin and analogues in the treatment of herpes simplex virus-II infections</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>The antitumour effect of cisplatin results from cross-linking and disruption of DNA when it binds to DNA bases, especially cytosine and guanine. Since herpes simplex virus (HSV) has a high cytosine and guanine content, cisplatin might be expected to have an antiviral effect against HSV. The 50% inhibitory concentration of cisplatin for HSV-II was 0.06 mg/1. Six of ten platinum analogues had 50% inhibition of plaques at ≤ 10 mg/1. We evaluated the in-vivo activity of cisplatin against the MS strain of HSV-II in the mouse genital HSV model. Mice were treated either intraperitoneally or intravaginally beginning at 3 or 51 h after inoculation. In the intraperitoneally treated groups infection rates were lower, but not significantly; 4 of 15 in the 3-h and 7 of 15 in the 51-h group, compared to 9 of 15 in the untreated control group (P&gt;0.18, chi-square test). Intravaginal cisplatin demonstrated a significant reduction of the infection rate from 10 of 15 untreated controls, compared to 5 of 18 in the 3-h and 5 of 17 in the 51-h group (P &lt; 0.05, chi-square test). No toxic effects of intravaginal cisplatin were seen in uninfected mice. These studies suggest that platinum containing drugs warrant further evaluation as a new class of antiviral agents with activity against HSV.</description><subject>Animals</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Cisplatin - pharmacology</subject><subject>Cisplatin - toxicity</subject><subject>Female</subject><subject>Herpes Simplex - drug therapy</subject><subject>herpes simplex virus 2</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Pharmacology. Drug treatments</subject><subject>Structure-Activity Relationship</subject><subject>Virus Replication - drug effects</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><recordid>eNo90M9rFDEUB_AgSl2rN6_CHMRTZ5sfM5nkKEW7C1sUaWnpJbzJvNjU-WWSXdr_3tRd9hTC9_Mejy8hHxldMqrF-SPYc6aXcqlY_YosWCVpyalmr8mCClqXTVWLt-RdjI-UUllLdUJOhMyjVC1IvH7Awo_lzqcwFTB2-89uKtA5b8E-F5MrrI9zD8mP_wWM0E-_txizLVKeTwEhDTimF_uAYc5R9MPc41Ox82Eby_U6W4c2-WmM78kbB33ED4f3lNx8_3Z9sSo3Py7XF183peVap9LxphUKhBb5lNZSbAVaUFIxbDvbOku1ppZT6KztEBg0bSc4ryropAKpxSn5st87h-lvPjeZwUeLfQ8jTttoWKUayWqV4dke2jDFGNCZOfgBwrNh1Lx0bHLHhmkjTe4480-Hvdt2wO6ID6Xm_PMhh2ihdwHGXOCRKc6bmvLMyj3zMeHTMYbwx8hGNLVZ3d2bza-r1e3Pq8rU4h_-ZZZj</recordid><startdate>198706</startdate><enddate>198706</enddate><creator>Snyder, Michael B.</creator><creator>Saravolatz, Louis D.</creator><creator>Markowitz, Norman</creator><creator>Pohlod, Donald</creator><creator>Taylor, R. Craig</creator><creator>Ward, Sarah G.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>198706</creationdate><title>The in-vitro and in-vivo efficacy of cisplatin and analogues in the treatment of herpes simplex virus-II infections</title><author>Snyder, Michael B. ; Saravolatz, Louis D. ; Markowitz, Norman ; Pohlod, Donald ; Taylor, R. Craig ; Ward, Sarah G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c299t-f27b38a393effbc0eb3eca8681ebdcbfc0990c20adccdea1a7bd32244ad68a693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Animals</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Cisplatin - pharmacology</topic><topic>Cisplatin - toxicity</topic><topic>Female</topic><topic>Herpes Simplex - drug therapy</topic><topic>herpes simplex virus 2</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Pharmacology. Drug treatments</topic><topic>Structure-Activity Relationship</topic><topic>Virus Replication - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Snyder, Michael B.</creatorcontrib><creatorcontrib>Saravolatz, Louis D.</creatorcontrib><creatorcontrib>Markowitz, Norman</creatorcontrib><creatorcontrib>Pohlod, Donald</creatorcontrib><creatorcontrib>Taylor, R. Craig</creatorcontrib><creatorcontrib>Ward, Sarah G.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Snyder, Michael B.</au><au>Saravolatz, Louis D.</au><au>Markowitz, Norman</au><au>Pohlod, Donald</au><au>Taylor, R. Craig</au><au>Ward, Sarah G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The in-vitro and in-vivo efficacy of cisplatin and analogues in the treatment of herpes simplex virus-II infections</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>1987-06</date><risdate>1987</risdate><volume>19</volume><issue>6</issue><spage>815</spage><epage>822</epage><pages>815-822</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><notes>istex:447A4F9BA6BF8D23BAC815B91A42CB24766B42A7</notes><notes>ark:/67375/HXZ-LRMHWPM4-5</notes><notes>ArticleID:19.6.815</notes><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-1</notes><notes>content type line 23</notes><abstract>The antitumour effect of cisplatin results from cross-linking and disruption of DNA when it binds to DNA bases, especially cytosine and guanine. Since herpes simplex virus (HSV) has a high cytosine and guanine content, cisplatin might be expected to have an antiviral effect against HSV. The 50% inhibitory concentration of cisplatin for HSV-II was 0.06 mg/1. Six of ten platinum analogues had 50% inhibition of plaques at ≤ 10 mg/1. We evaluated the in-vivo activity of cisplatin against the MS strain of HSV-II in the mouse genital HSV model. Mice were treated either intraperitoneally or intravaginally beginning at 3 or 51 h after inoculation. In the intraperitoneally treated groups infection rates were lower, but not significantly; 4 of 15 in the 3-h and 7 of 15 in the 51-h group, compared to 9 of 15 in the untreated control group (P&gt;0.18, chi-square test). Intravaginal cisplatin demonstrated a significant reduction of the infection rate from 10 of 15 untreated controls, compared to 5 of 18 in the 3-h and 5 of 17 in the 51-h group (P &lt; 0.05, chi-square test). No toxic effects of intravaginal cisplatin were seen in uninfected mice. These studies suggest that platinum containing drugs warrant further evaluation as a new class of antiviral agents with activity against HSV.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>3610908</pmid><doi>10.1093/jac/19.6.815</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0305-7453
ispartof Journal of antimicrobial chemotherapy, 1987-06, Vol.19 (6), p.815-822
issn 0305-7453
1460-2091
language eng
recordid cdi_proquest_miscellaneous_14876158
source Oxford University Press:Jisc Collections:Oxford Journal Archive: Access period 2024-2025
subjects Animals
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Biological and medical sciences
Cisplatin - pharmacology
Cisplatin - toxicity
Female
Herpes Simplex - drug therapy
herpes simplex virus 2
Medical sciences
Mice
Pharmacology. Drug treatments
Structure-Activity Relationship
Virus Replication - drug effects
title The in-vitro and in-vivo efficacy of cisplatin and analogues in the treatment of herpes simplex virus-II infections
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-23T06%3A27%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20in-vitro%20and%20in-vivo%20efficacy%20of%20cisplatin%20and%20analogues%20in%20the%20treatment%20of%20herpes%20simplex%20virus-II%20infections&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Snyder,%20Michael%20B.&rft.date=1987-06&rft.volume=19&rft.issue=6&rft.spage=815&rft.epage=822&rft.pages=815-822&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/19.6.815&rft_dat=%3Cproquest_cross%3E14876158%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c299t-f27b38a393effbc0eb3eca8681ebdcbfc0990c20adccdea1a7bd32244ad68a693%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=14876158&rft_id=info:pmid/3610908&rfr_iscdi=true